Pharma Vendor Onboarding: Security and Privacy Review Explained
What pharma vendor security and privacy reviews cover, why they take time, what vendors should prepare, and how marketers can speed them up.
The short answer
Before a new marketing vendor can work with a pharma company, it typically goes through security and privacy review. Reviewers check how the vendor protects data, what personal or health data it handles, where data comes from and under what consent, how it is shared, and what contracts are needed. Vendors that prepare documentation in advance, and marketers who start reviews early with a clear data flow description, move through much faster.
Marketers often find a promising partner, agree on a test, and then wait months for onboarding. Security and privacy review protects the company and its customers. It does not have to be slow if both sides prepare.
What reviews cover
| Area | Questions |
|---|---|
| Security | How data is stored, encrypted, accessed; incident response; certifications |
| Privacy | What personal data is processed; legal basis; consent; sensitive data |
| Data sourcing | Where third-party data comes from and with what permissions |
| Data sharing | Who receives data; subprocessors; international transfers |
| Health data | HIPAA roles, if any; state health privacy laws; de-identification |
| Contracts | Data processing terms, business associate agreements where needed |
Documents vendors should have ready
- Security certifications or independent audit reports.
- Completed standard security questionnaire.
- Privacy policy and data use statement.
- Data flow diagram for the proposed work.
- Data sourcing and consent documentation.
- List of subprocessors.
- Standard data processing agreement.
How marketers can speed things up
- Start review when you first consider a vendor, not after choosing.
- Write a one-page description of the proposed work and data flows.
- Identify whether health data or HCP data is involved.
- Involve your privacy team in vendor selection.
- Ask procurement which review tier applies.
Risk tiers
Many companies tier vendors by risk:
| Tier | Example |
|---|---|
| Low | Vendor receives no personal data |
| Medium | Vendor processes HCP or consumer data under contract |
| High | Vendor handles health data, sensitive data, or large volumes |
Higher tiers take longer. Designing work to avoid unnecessary data sharing can lower the tier.
Common mistakes
- Starting review after the campaign is planned.
- Vague descriptions of data flows.
- Vendors without basic documentation.
- Sharing data before contracts are signed.
A sample one-page data flow description
Privacy and security teams move faster when they receive a short, plain description up front. A useful format:
- Purpose. "Test whether NPI-matched CTV reaches target rheumatologists at a lower cost per target reached than our current partner."
- Data we send. NPI list of 8,000 target HCPs. No patient data. No consumer data.
- Data the vendor uses. Its HCP identity graph, built from professional data sources described in attached documentation.
- Data we receive. NPI-level delivery counts and aggregated reach. No device IDs.
- Who else receives data. Our measurement partner receives NPI-level exposure files under its existing contract.
- Retention. Vendor deletes our list 90 days after campaign end.
- Health data involved? No patient health data. Prescribing data stays with the measurement partner.
That page lets reviewers assign a risk tier quickly and ask focused questions.
Questions reviewers commonly ask
- Is any data about patients or consumers involved, even indirectly?
- Does the vendor combine our data with other clients' data?
- Can the vendor re-identify de-identified data?
- Where is data stored and processed, including subprocessors?
- What happens to our data at contract end?
- Has the vendor had a security incident, and how was it handled?
Vendors that answer these in writing before being asked tend to clear review in weeks rather than months.
Practical takeaway
For any new marketing vendor, send your privacy team a one-page data flow description in the first week of discussions. That page often decides how long the whole review will take.
Frequently asked questions
Why do pharma vendor reviews take so long?
They involve security, privacy, legal, and procurement teams, often in sequence, and vendors may not have documentation ready.
What documents should vendors prepare?
Security certifications or audit reports, security questionnaire answers, privacy policy, data flow diagrams, data sourcing and consent documentation, and standard contract terms.
Can marketing start work before review is complete?
Usually not with real data. Some companies allow limited planning work. Start reviews early.
Sources
- NIST Privacy Framework
- HHS, HIPAA for Professionals
- FTC, Health Breach Notification Rule: The Basics for Business
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.